Company Overview
Snapshot
Founded in March 2016 by Arik Ben Ishay, Johanan May, and Israel Sarussi, Biobeat operates with 11–50 employees. The company has raised a total of $68.6M across 7 funding rounds from 7 investors.
Business overview
Biobeat is a med-tech company specializing in FDA-cleared, cuffless blood pressure monitoring solutions. Its core technology utilizes a proprietary patented PPG sensor embedded in a small, non-invasive device worn on the patient’s chest for 24 hours. This technology not only measures blood pressure but also extracts heart rate and cardiac output. The device and automated platform deliver detailed reports to clinicians, enabling quick evaluation, treatment plans, and adjustments based on quantitative measures and trends. Biobeat's solution aims to eliminate white coat and masked hypertension, serving the healthcare and life sciences sectors with a focus on medical devices and patient remote monitoring.
Strategic signal
In March 2024, Biobeat introduced a new blood pressure patch, signaling a continued focus on innovative, non-invasive monitoring solutions. This development reinforces the company's commitment to enhancing patient comfort and data accuracy, which is critical for remote patient monitoring and could expand its market reach within the digital healthcare sector.
Log in to access full profile ›Company Intelligence Q&A
- What is Biobeat's primary offering?
- Biobeat provides FDA-cleared, cuffless blood pressure monitoring through a small, non-invasive sensor placed on the patient’s chest for 24 hours, measuring blood pressure, heart rate, and cardiac output.
- Which organization did Biobeat join in September 2022?
- In September 2022, Biobeat joined the Innovators' Network at the American Heart Association Center for Health Technology & Innovation.
- When did Biobeat's remote vital sign monitoring system receive FDA clearance?
- In March 2022, Biobeat's remote vital sign monitoring system received FDA clearance.
- What significant regulatory approval did Biobeat receive in February 2020?
- In February 2020, Biobeat's wearable wristwatch and patch received CE Mark approval for non-invasive cuffless monitoring of blood pressure, cardiac output, stroke volume, pulse, and saturation.